Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Clinical Immunology

The Biology of the "Muffled Signal": How JAK1 Deficiency is Diagnosed

At a Glance

Partial JAK1 deficiency is diagnosed by combining JAK1 genetic testing with functional immune assays. Doctors test how a child’s cells respond to interferon-gamma, including STAT1 activation and macrophage killing, because routine blood counts and immunoglobulins may be normal.

Understanding the biology of your child’s diagnosis requires looking past the surface of standard medical tests. Because partial JAK1 deficiency is so rare, your child’s routine blood work—like a complete blood count (CBC) or antibody levels (immunoglobulins) —may look perfectly normal [1]. To find the answer, doctors must look deep into the “instruction manual” of the cells (the genes) and the “communication network” of the immune system (the signaling pathways).

The Signaling Glitch: How JAK1 Works

Inside every person’s immune system is a specialized team of cells called macrophages [1]. Their job is to eat and destroy bacteria. However, some bacteria, specifically mycobacteria, are “tough” and can survive inside the macrophage unless the cell receives a loud, clear signal to kill them [1].

That signal is a protein called Interferon-gamma (IFN-γ). Think of the IFN-γ receptor as the essential “receiver” on the outside of the cell that catches the signal, while JAK1 and JAK2 are kinases inside the cell that help transmit it down the line [1][2].

  • In a typical cell: The IFN-γ signal hits the receptor, which uses JAK1 and JAK2 to trigger a chain reaction activating STAT1, which travels to the cell’s control center to tell the macrophage to activate its antimicrobial mechanisms and kill the bacteria [1].
  • In partial JAK1 deficiency: The mutation is hypomorphic, meaning it is “partial” or “leaky.” The transmission is muffled [1]. The signal is sent and caught by the receptor, but the macrophage only hears a whisper inside. Because it doesn’t get the full command, the bacteria continue to live and multiply inside the child’s own immune cells [1].

The Diagnostic Process

A definitive diagnosis for this condition requires two distinct types of evidence, interpreted by experts in genetics and immunology:

  1. Genetic Testing (The Instructions): Doctors may use targeted gene panels, Whole-Exome Sequencing (WES), or whole-genome sequencing to look for mutations in the JAK1 gene [1]. For this condition, the reported form may be autosomal recessive if pathogenic variants are found on both copies of the gene (one from each parent) [1].
  2. Functional Assays (The Proof): Because not every genetic “typo” causes disease, doctors often must prove the mutation actually stops the immune system from working. They do this by taking a sample of the child’s cells and “challenging” them with IFN-γ in a lab [1][3]. They look for:
    • Impaired Signaling: Measuring if proteins like STAT1 (the next messenger in the line) are activated correctly [2].
    • Defective Killing: Observing if the child’s macrophages fail to destroy mycobacteria in a controlled environment [1].

What to Look for on the Lab Report

When reviewing pathology or immunology reports with your doctor, you may see specific terms that confirm this diagnosis:

  • JAK1 Variant: The report should name the specific mutation and classify it as “pathogenic” or “likely pathogenic” [1]. Expert genetic and immunologic correlation is required to interpret variants of uncertain significance.
  • Reduced IFN-γ Response: Look for notes indicating that cells showed a “blunted” or “impaired” response when treated with Interferon-gamma or Interferon-alpha [1].
  • M. avium or M. chelonae: These are examples of “atypical” environmental mycobacteria that may be encountered in children with this deficiency [4][5].

Avoiding Misdiagnosis

Because this condition mimics other diseases, it is frequently confused with more common problems:

  • Tuberculosis vs. BCG: A child with MSMD might have an infection from the BCG vaccine that clinically resembles multidrug-resistant tuberculosis (MDR-TB) [6]. However, the BCG vaccine contains an attenuated (weakened) strain of M. bovis, and specialized laboratory cultures and molecular testing are needed to distinguish it from MDR-TB to ensure the right treatments.
  • Other MSMDs: There are many different genetic “glitches” that cause MSMD [7]. For example, defects in IFNGR1 or STAT1 can look identical to JAK1 deficiency on the surface [8][9]. Only detailed genetic and functional testing can tell them apart.
  • Secondary Immunodeficiencies: Doctors must also rule out other causes of a weakened immune system, such as HIV or certain medications that block the JAK pathway (like ruxolitinib) [10][11].

By confirming that the problem is specifically a partial JAK1 deficiency, your care team can move away from “guessing” and toward a treatment plan tailored to your child’s unique biological needs.

Common questions in this guide

How is partial JAK1 deficiency diagnosed?
Doctors usually combine genetic testing with functional immune testing. A gene panel, whole-exome sequencing, or whole-genome sequencing can identify JAK1 variants, while laboratory tests examine interferon-gamma signaling and whether macrophages can kill mycobacteria.
Can my child's routine blood tests be normal with JAK1 deficiency?
Yes. A complete blood count and immunoglobulin levels may be normal even when partial JAK1 signaling is impaired, so normal screening tests do not rule it out. Specialized genetic and functional immune tests may still be needed.
What does a hypomorphic JAK1 variant mean?
A hypomorphic variant is a partial or “leaky” change that leaves some JAK1 activity rather than eliminating it completely. The interferon-gamma signal can reach the cell but is transmitted weakly, which may leave macrophages less able to control mycobacteria.
What do functional immune tests show?
These tests expose a child's cells to interferon-gamma and measure downstream signaling, such as activation of STAT1. They may also assess whether macrophages can destroy mycobacteria in the laboratory; abnormal results support the clinical significance of a JAK1 variant.
How do doctors distinguish JAK1 deficiency from other MSMD conditions?
Genetic testing looks for changes in JAK1 and other genes, including IFNGR1 and STAT1. Functional results and the child's infection history are interpreted together to distinguish these inherited conditions from one another and from secondary immune problems.
Could a BCG or environmental mycobacterial infection have another cause?
Yes. BCG infection, M. avium, or M. chelonae can occur for several reasons and do not by themselves prove JAK1 deficiency. Doctors use specialized cultures or molecular tests, along with genetic and immune testing, to distinguish BCG infection from multidrug-resistant tuberculosis and identify the underlying immune problem.
Does partial JAK1 deficiency run in families?
It may follow autosomal recessive inheritance when pathogenic variants are present in both JAK1 copies, with one variant inherited from each parent. A genetics professional can explain family testing and what the results may mean for relatives.

Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria.

    Daza-Cajigal V, Albuquerque AS, Young DF, et al.

    Frontiers in immunology 2022; (13()):888427 doi:10.3389/fimmu.2022.888427.

    PMID: 36159783
  2. 2

    IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy.

    Ivashkiv LB

    Nature reviews. Immunology 2018; (18(9)):545-558 doi:10.1038/s41577-018-0029-z.

    PMID: 29921905
  3. 3

    Loss of Janus Associated Kinase 1 Alters Urothelial Cell Function and Facilitates the Development of Bladder Cancer.

    Daza-Cajigal V, Albuquerque AS, Pearson J, et al.

    Frontiers in immunology 2019; (10()):2065 doi:10.3389/fimmu.2019.02065.

    PMID: 31552026
  4. 4

    An atypical mycobacterial infection while on Janus kinase inhibitor therapy.

    Valek SA, Black TA, Aboul-Fettouh N, Rogge MN

    Dermatology online journal 2025; (31(2)) doi:10.5070/D331265289.

    PMID: 40991493
  5. 5

    Pseudotumoral Pulmonary Mycobacterium avium Disease in a Patient on Ruxolitinib Therapy.

    Constantin AA, Iorga AL, Gaburici AD, Leonte I

    Diagnostics (Basel, Switzerland) 2026; (16(7)) doi:10.3390/diagnostics16071069.

    PMID: 41975780
  6. 6

    Molecular, Immunological, and Clinical Features of 16 Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease.

    Sarrafzadeh SA, Nourizadeh M, Mahloojirad M, et al.

    Journal of clinical immunology 2019; (39(3)):287-297 doi:10.1007/s10875-019-0593-4.

    PMID: 30715640
  7. 7

    Inherited human IFN-γ deficiency underlies mycobacterial disease.

    Kerner G, Rosain J, Guérin A, et al.

    The Journal of clinical investigation 2020; (130(6)):3158-3171.

    PMID: 32163377
  8. 8

    Genetic and Functional Identifying of Novel STAT1 Loss-of-Function Mutations in Patients with Diverse Clinical Phenotypes.

    Chen X, Chen J, Chen R, et al.

    Journal of clinical immunology 2022; (42(8)):1778-1794 doi:10.1007/s10875-022-01339-w.

    PMID: 35976469
  9. 9

    Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1.

    Pedraza-Sánchez S, Lezana-Fernández JL, Gonzalez Y, et al.

    Frontiers in immunology 2017; (8()):1651 doi:10.3389/fimmu.2017.01651.

    PMID: 29270166
  10. 10

    Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.

    Anand K, Burns EA, Ensor J, et al.

    Clinical lymphoma, myeloma & leukemia 2020; (20(1)):18-23 doi:10.1016/j.clml.2019.08.008.

    PMID: 31699655
  11. 11

    Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.

    Liu X, Zhu X, Zhou X, et al.

    Frontiers in immunology 2022; (13()):1012643 doi:10.3389/fimmu.2022.1012643.

    PMID: 36263041

This page is for informational purposes only and does not constitute medical advice. A pediatric immunologist, geneticist, or infectious-disease specialist should interpret your child's tests and guide care.